FDA dings Hospira for ‘misleading’ ads for blood drug

The U.S. Food and Drug Administration has admonished Hospira Inc. for overstating the capabilities of Voluven, a plasma substitute designed to increase patients’ blood volume after surgery or trauma. In an apparent bid to boost sales, Hospira has improperly claimed that Voluven can be used during major abdominal surgery, to prime cardiac pumps and to treat swelling, according to an FDA letter to a Hospira executive.

Click here to read more…

0 Responses to “FDA dings Hospira for ‘misleading’ ads for blood drug”

  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 435 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.

%d bloggers like this: